A detailed history of Black Rock Inc. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 9,025,007 shares of ALNY stock, worth $2.19 Billion. This represents 0.03% of its overall portfolio holdings.

Number of Shares
9,025,007
Previous 8,521,115 5.91%
Holding current value
$2.19 Billion
Previous $1.63 Billion 17.3%
% of portfolio
0.03%
Previous 0.04%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$146.51 - $198.2 $73.8 Million - $99.9 Million
503,892 Added 5.91%
9,025,007 $1.35 Billion
Q4 2023

Feb 13, 2024

BUY
$151.41 - $196.57 $19.4 Million - $25.2 Million
128,111 Added 1.53%
8,521,115 $1.63 Billion
Q3 2023

Nov 13, 2023

BUY
$170.77 - $211.65 $1.17 Million - $1.45 Million
6,842 Added 0.08%
8,393,004 $1.49 Billion
Q2 2023

Aug 11, 2023

SELL
$185.01 - $212.05 $30.1 Million - $34.5 Million
-162,800 Reduced 1.9%
8,386,162 $1.59 Billion
Q1 2023

May 12, 2023

BUY
$182.66 - $235.53 $10.9 Million - $14 Million
59,582 Added 0.7%
8,548,962 $1.71 Billion
Q4 2022

Feb 13, 2023

BUY
$185.53 - $241.31 $152 Million - $198 Million
820,702 Added 10.7%
8,489,380 $2.02 Billion
Q3 2022

Nov 14, 2022

BUY
$138.54 - $232.0 $831,655 - $1.39 Million
6,003 Added 0.08%
7,668,678 $1.53 Billion
Q2 2022

Aug 12, 2022

BUY
$120.42 - $169.29 $6.47 Million - $9.09 Million
53,721 Added 0.71%
7,662,675 $1.12 Billion
Q1 2022

May 12, 2022

SELL
$127.18 - $173.91 $7.94 Million - $10.9 Million
-62,448 Reduced 0.81%
7,608,954 $1.24 Billion
Q4 2021

Feb 10, 2022

SELL
$159.56 - $209.29 $199 Million - $262 Million
-1,249,570 Reduced 14.01%
7,671,402 $1.3 Billion
Q3 2021

Nov 09, 2021

BUY
$169.75 - $207.73 $38.1 Million - $46.6 Million
224,569 Added 2.58%
8,920,972 $1.68 Billion
Q2 2021

Aug 11, 2021

BUY
$128.63 - $176.89 $1.12 Billion - $1.54 Billion
8,696,403 New
8,696,403 $1.47 Billion

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $29.9B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.